Related Experiment Video
Updated: Apr 28, 2026
Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
Published on: February 2, 2024
PHLDA3 is a novel tumor suppressor of pancreatic neuroendocrine tumors
Rieko Ohki1, Kozue Saito2, Yu Chen2
1Divisions of Refractory Cancer Research, rohki@ncc.go.jp.
Abstract:
The molecular mechanisms underlying the development of pancreatic neuroendocrine tumors (PanNETs) have not been well defined. We report here that the genomic region of the PHLDA3 gene undergoes loss of heterozygosity (LOH) at a remarkably high frequency in human PanNETs, and this genetic change is correlated with disease progression and poor prognosis. We also show that the PHLDA3 locus undergoes methylation in addition to LOH, suggesting that a two-hit inactivation of the PHLDA3 gene is required for PanNET development. We demonstrate that PHLDA3 represses Akt activity and Akt-regulated biological processes in pancreatic endocrine tissues, and that PHLDA3-deficient mice develop islet hyperplasia. In addition, we show that the tumor-suppressing pathway mediated by MEN1, a well-known tumor suppressor of PanNETs, is dependent on the pathway mediated by PHLDA3, and inactivation of PHLDA3 and MEN1 cooperatively contribute to PanNET development. Collectively, these results indicate the existence of a novel PHLDA3-mediated pathway of tumor suppression that is important in the development of PanNETs.
Insights
Loss of heterozygosity and methylation of the PHLDA3 gene are frequent in pancreatic neuroendocrine tumors (PanNETs), indicating a two-hit mechanism. PHLDA3 acts as a tumor suppressor by repressing Akt activity, crucial for PanNET development.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Pancreatic neuroendocrine tumors (PanNETs) are rare neoplasms with incompletely understood molecular drivers.
- Identifying key genetic alterations is crucial for understanding PanNET pathogenesis and developing targeted therapies.
Purpose of the Study:
- To elucidate the molecular mechanisms and genetic alterations involved in pancreatic neuroendocrine tumor development.
- To investigate the role of the PHLDA3 gene in PanNET pathogenesis and its relationship with known tumor suppressors like MEN1.
Main Methods:
- Analysis of loss of heterozygosity (LOH) and methylation at the PHLDA3 locus in human PanNET samples.
- Functional studies in pancreatic endocrine tissues and mouse models to assess PHLDA3's role in regulating Akt signaling and cell proliferation.
- Investigation of the interplay between PHLDA3 and MEN1 tumor suppressor pathways.
Main Results:
- High-frequency LOH and methylation of the PHLDA3 gene were observed in PanNETs, suggesting a two-hit inactivation mechanism.
- PHLDA3 was found to repress Akt activity, and its deficiency led to islet hyperplasia in mice.
- Inactivation of PHLDA3 cooperates with MEN1 inactivation in promoting PanNET development, highlighting a novel tumor suppressor pathway.
Conclusions:
- A novel PHLDA3-mediated tumor suppressor pathway is critical in pancreatic neuroendocrine tumor development.
- Dual inactivation of PHLDA3 and MEN1 contributes significantly to PanNET pathogenesis.
- PHLDA3 represents a potential therapeutic target for PanNETs.
